Board of directors

Peter Ehrenheim

Peter Ehrenheim

Chairman of the board

Education: M.Sc. in Mechanical Engineering

Elected to the board: 2019-09-09

Chairman from 2019-09-09



Past experience: Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Shares: 162 537 and 439 868 via Färjsundet AB.

Thomas Pollare

Thomas Pollare

Board director

Education: M.D., Ph.D

Elected to the board: 2013-09-24




Past experience: Former CEO Global Medical Investments, former partner with venture capital firm 3i. VP roles at Pharmacia and Schering-Plough Research Institute. Board experience in major corporations as well as start-ups and venture investing.

Shares: 145 639 (via Oncolution AB) & warrants 15 000.

Thomas Eklund

Thomas Eklund

Board Director

Education: MBA Stockholm School of Economics

Elected to the board: 2019-09-09




Past experience: Independent advisor, board member and investor. Head of Investor Growth Capital 2001 to 2013. Board member and lead investor in Swedish Orphan, Carmel Pharma, Entific Medical, Vardapoteket and Memira. Previously Investment Director at AAC Capital and Director Handelsbanken Market, corporate finance. Presently chairman in Biotage AB and Sedana Medical AB and director in Boule Diagnostics, Immedica Pharma AB, Swedencare AB and Surgical Science AB. Advisor to Impilo AB and Investor AB.

Shares 555 556

Kirsti Gjellan

Kirsti Gjellan

Board Director

Education: M.Sc. (Pharm), Ph.D (Pharm Technology)

Elected to the board: 2018-05-18




Past experience: More than 30 years of experience from Pharmaceutical industry covering Discovery, Proof of Concept, Pharmaceutical Development, Quality Operations in Manufacturing, EHS, Right First Time/Lean/Six Sigma and site leader management as well as managing director. All work experience has been generated in the dynamic between local and global organizations to create the most business value. Has worked as a Leader/manager and Change Agent since 1989.

Shares: 12 856 & warrants 15 000.

Lena Söderström

Lena Söderström

Board Director

Education: B.Sc. & Executive MBA in Medical Science from Uppsala University

Elected to the board: 2018-05-18




Past experience: CEO of Senzime. Thirty years experience in management positions in international pharmaceutical companies and the medical device industry. Broad range of experience includes positions e.g. people and project management, business development, international marketing and manufacturing. Board member of Uppsala universitet Holding AB (UUAB), SLU Holding AB, Genovis AB, Dicot AB and member of the Chamber Council at Stockholm Chamber of Commerce.

Shares: 20 000 & warrants 15 000.

Patrick Van de Velde

Patrick Van de Velde

Board Director

Education: M.Sc. Industrial Engineering Biochemistry, MBA

Elected to the board: 2017-06-07




Past experience: Current General Manager and Board Member Promega Biotech AB, previous head of marketing Europe at GE Health and sales & business development manager at Sigma Aldrich Sweden.

Shares: 15 500 & warrants 15 000.

Yong Chul Shin

Yong Chul Shin

Board Director

Education: B.Sc., Ph.D

Elected to the board: 2017-06-07




Past experience: Current CEO and Chairman of Amicogen Inc. South Korea. Former professor of Gyungsang National University, former committee member of the Korean Food and Drug Administration. Previous journal editor of the Korea Society for Microbiology and Biotechnology.

Shares 3 007 896 (via Amicogen Inc.).

All board members are independent in relation to the Company and its senior executives as well as in relation to major shareholders.